Elanco Animal Health (ELAN)vsTeva Pharma Industries Ltd ADR (TEVA)
ELAN
Elanco Animal Health
$23.17
+1.36%
HEALTHCARE · Cap: $11.98B
TEVA
Teva Pharma Industries Ltd ADR
$37.09
+2.04%
HEALTHCARE · Cap: $42.84B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 245% more annual revenue ($17.32B vs $5.02B). TEVA leads profitability with a 4.1% profit margin vs -4.0%. TEVA appears more attractively valued with a PEG of 0.67. ELAN earns a higher WallStSmart Score of 52/100 (C-).
ELAN
Buy52
out of 100
Grade: C-
TEVA
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.5%
Fair Value
$19.85
Current Price
$23.17
$3.32 premium
Intrinsic value data unavailable for TEVA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 440.5% YoY
Reasonable price relative to book value
Earnings expanding 72.2% YoY
Growing faster than its price suggests
Areas to Watch
Expensive relative to growth rate
ROE of -3.0% — below average capital efficiency
Distress zone — elevated risk
Currently unprofitable
4.1% margin — thin
Operating margin of 4.0%
Premium valuation, high expectations priced in
Revenue declined 0.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : ELAN
The strongest argument for ELAN centers on EPS Growth, Price/Book. Revenue growth of 10.2% demonstrates continued momentum.
Bull Case : TEVA
The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.67 suggests the stock is reasonably priced for its growth.
Bear Case : ELAN
The primary concerns for ELAN are PEG Ratio, Return on Equity, Altman Z-Score.
Bear Case : TEVA
The primary concerns for TEVA are Profit Margin, Operating Margin, P/E Ratio. A P/E of 61.3x leaves little room for execution misses. Debt-to-equity of 2.18 is elevated, increasing financial risk.
Key Dynamics to Monitor
ELAN profiles as a turnaround stock while TEVA is a value play — different risk/reward profiles.
ELAN carries more volatility with a beta of 1.68 — expect wider price swings.
ELAN is growing revenue faster at 10.2% — sustainability is the question.
TEVA generates stronger free cash flow (307M), providing more financial flexibility.
Bottom Line
ELAN scores higher overall (52/100 vs 49/100) and 10.2% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Elanco Animal Health
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures and markets products for pets and farm animals. The company is headquartered in Greenfield, Indiana.
Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?